Skip to main content

Table 3 Association of clinical, pathological and genomic characteristics with PFS and OS in the control group

From: Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer

Characteristics N
(107)
Progression Free Survival Overall Survival
    HR 95% CI P HR 95% CI p
Sex Females 39 1    1   
  Males 68 0.97 0.65-1.45 0.893 0.83 0.51-1.30 0.397
Age ≤ 65 years 60 1    1   
  >65 years 47 0.78 0.51-1.15 0.197 0.94 0.61-1.44 0.782
ECOG PS 0 83 1    1   
  1-2 24 1.34 0.84-2.31 0.196 2.32 1.68-6.23 0.0004
Previous adjuvant CT No 75 1    1   
  Yes 32 1.13 0.74-1.75 0.562 0.77 0.49-1.22 0.268
No. of metastatic sites 1 57 1    1   
  >1 50 1.10 0.75-1.62 0.632 0.88 0.57-1.34 0.542
Liver-only metastases No 68 1    1   
  Yes 39 0.81 0.54-1.19 0.270 0.97 0.63-1.51 0.901
High CEA level No 85 1    1   
  Yes 22 1.45 0.91-2.68 0.109 1.91 1.22-4.36 0.010
-1498 C/C 25 1    1   
  C/T 55 1.09 0.68-1.76 0.719 0.89 0.50-1.55 0.662
  T/T 27 0.89 0.50-1.54 0.653 0.73 0.36-1.39 0.311